Inhibrx Biosciences, Inc. (INBX) Stock Analysis

Inhibrx Biosciences, Inc. (INBX) is a publicly traded company in the HEALTHCARE sector. It trades at $93.63, carries a market capitalization of $1.46B. This page summarizes the public market data, fundamentals, and frequently asked questions for INBX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $93.63
• Market Cap: $1.46B
• EPS: $-8.39
• 52-Week High: $155.29
• 52-Week Low: $12.80

Market Sentiment

Inhibrx Biosciences, Inc. currently has a Bullish sentiment score of 0.23.

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California, focused on developing cutting-edge biological therapeutics for cancer and other serious diseases. With a diverse pipeline that features monoclonal antibodies and multi-specific therapeutics, Inhibrx aims to enhance treatment efficacy and safety, ultimately improving patient outcomes. By harnessing its proprietary technologies, the company is uniquely positioned to drive innovation in the...

GNG Research Analysis

GNG Research scores Inhibrx Biosciences, Inc. (INBX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for INBX.

Frequently Asked Questions

Does INBX pay dividends?

Inhibrx Biosciences, Inc. (INBX) does not currently pay a regular dividend.

What is INBX's market cap?

Inhibrx Biosciences, Inc. (INBX) has a market capitalization of $1.46B with a current stock price of $93.63.